ALK and cancer: Taking into account potential cancer type differences, we found that ROS1 (63% vs. 44%; Fisher’s exact test P < 0.0001) and ALK fusions (50% vs. 44%, Fisher’s exact test P = 0.006) remain more prevalent in female lung cancer patients (Supplementary Fig. 3A).